Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07000149
PHASE1

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC). The Phase III part of the study will no longer be conducted.

Official title: A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

9

Start Date

2025-07-28

Completion Date

2027-01-29

Last Updated

2026-08-03

Healthy Volunteers

No

Interventions

DRUG

Volrustomig

Volrustomig will be administered as an intravenous (IV) infusion.

DRUG

Casdatifan

Casdatifan will be administered orally.

Locations (3)

Research Site

Elizabeth Vale, Australia

Research Site

Busan, South Korea

Research Site

Seoul, South Korea